BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders


1/4/2008 7:59:54 AM

LAKE FOREST, Ill., Jan. 3 /PRNewswire/ -- TAP Pharmaceutical Products Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of TAK-390MR in the treatment of acid related diseases and treatment and maintenance of patients with erosive esophagitis and non-erosive reflux disease. TAK-390MR is a proton pump inhibitor that utilizes a novel delivery system.

"This compound and its novel delivery system is a promising next step in the management of erosive and non-erosive esophagitis," said Nancy Joseph Ridge, M.D., vice president of research and development at TAP. "The development of TAK-390MR is another example of our experience and expertise in this therapeutic area and reinforces our commitment to patients."

The NDA filing, which was entirely electronic (eCTD) from data collection to submission, is based on global studies conducted in more than 20 countries. These studies evaluated more than 6,000 subjects with erosive and non-erosive GERD.

About TAP Pharmaceutical Products Inc.

TAP Pharmaceutical Products Inc., located in Lake Forest, Ill., is a joint venture between Abbott, headquartered in Abbott Park, Ill., and Takeda Pharmaceutical Company Limited, of Osaka, Japan. TAP markets Prevacid(R) and Lupron Depot(R) (leuprolide acetate for depot suspension). For more information about TAP Pharmaceutical Products Inc., and its products, visit the company's web site at http://www.tap.com.

CONTACT: Media, Amy Martin, +1-847-582-6019, or Geoff Curtis,
+1-312-284-4701, both for TAP Pharmaceutical Products Inc.

Web site: http://www.tap.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES